Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	21.95B -24.5%
Revenue (ttm)	6.12B +2.9%
Net Income	1.10B -9.7%
EPS	1.09 -9.2%
Shares Out	1.02B
PE Ratio	19.82
Forward PE	16.75
Dividend	0.40 (1.77%)
Ex-Dividend Date	May 26, 2026

Volume	3,559,412
Open	21.72
Previous Close	21.65
Day's Range	21.46 - 21.72
52-Week Range	17.96 - 29.30
Beta	-0.31
Analysts	Buy
Price Target	28.11 (+30.08%)
Earnings Date	Aug 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 6,003
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2025, SHE:002262's revenue was 5.91 billion, an increase of 3.75% compared to the previous year's 5.70 billion. Earnings were 1.06 billion, a decrease of -7.54%.

Analyst Summary

According to 4 analysts, the average rating for 002262 stock is "Buy." The 12-month stock price target is ¥28.11, which is an increase of 30.08% from the latest price.

Price Target

¥28.11

(30.08% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 16, 2026

Data Sources Report a data error